23andMe today announced it has raised $115 million in a Series E financing round that will go toward expanding the company's operations and "maximize the potential of its direct-to-consumer product in the US and abroad."

Fidelity Management & Research led the financing and was joined by new investors Casdin Capital, WuXi Healthcare Ventures, and Xfund. Existing investors Illumina, New Enterprise Associates, MPM Capital, and Google Ventures also participated in the round. In the financing, the most impressive is WuXi Healthcare Ventures joined it. 23andMe also said it will enter into the China market with the cooperate with WuXi Healthcare Ventures.

23andMe said that it expects to launch a new user experience that will include carrier status reports in the US, along with enhanced tools and functionality for customers, by the end of the year. The financing will also be used for strategic infrastructure, such as new laboratory space for therapeutic research and a new next-generation sequencing laboratory, and other investments aimed at long-term growth.

Earlier in the year, 23andMe received clearance from the US Food and Drug Administration to market a test for Bloom syndrome directly to customers. The FDA had warned the company in 2013 to stop marketing health-related genetic test results directly to customers through its Personal Genome Service until it received the agency's regulatory clearance or approval.